Results from a large retrospective data analysis published in the American Journal of Transplantation (AJT) today, showed that liver transplantation patients who were treated early with Advagraf experienced a significantly increased graft survival benefit of 8% at 3 years post-transplant compared with patients treated with the current standard of care, tacrolimus immediate release (twice daily).
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7451251-advagraf-prolonged-release-tacrolimus/
ACG – the leading partner for pharmaceutical industry’s myriad requirements – is strengthening its product portfolio by launching several new machines at CPhI/P-MEC India, to be held during 2-4 December 2014, at Bombay Exhibition Centre, Mumbai.
P-MEC India, co-located with CPhI India, is one of the ‘must-attend’ events in the international pharmaceutical industry. With a booth that spreads over 1,000 sq. m., ACG will be displaying several new machines including the all-new ACG X.One Technology that reinvents the 12-bar safety features; Protab, a tablet press suited for small to medium batch sizes, and many more.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7391551-ACG-Launch-New-Machines-at-CPhI/
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
The Epilepsy Foundation launched the “Talk About It!” public service announcement featuring actor Greg Grunberg to raise awareness and encourage open dialogue about epilepsy and seizures. Greg, best known for his roles on Heroes, Alias, and Felicity, has an adult son who lives with epilepsy, a condition that affects nearly 3 million Americans. The Epilepsy Foundation and Greg teamed up for this PSA, sponsored by Sunovion Pharmaceuticals Inc., to drive much needed conversation about epilepsy – bringing the condition out of the shadows and honoring a community that deserves better awareness and understanding. More information about the PSA and initiative can be found by visiting the Epilepsy Foundation at epilepsy.com.
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the initiation of production of The PBA Film Project (working title), the first-ever documentary to provide an intimate look at real people living with a little-known neurologic condition called PseudoBulbar Affect (PBA). The award-winning filmmaker team of The PBA Film Project includes co-directors Doug Blush and Lisa Klein (Of Two Minds) and producer Julian Cautherley (The Crash Reel).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7266955-avanir-pharmaceuticals-pseudobulbar-affect-pba-documentary/
Mark your calendars now – those leftover OTC and prescriptions in your medicine cabinet have got to go!
Chances are, if you open your medicine cabinet, you’ll find some some leftover medication that “might come in handy someday.” The reality is, those medications may have expired and are either ineffective or may cause more harm than you know. With cold and flu season upon us, it’s a great time to purge the medicine cabinet. Better to prepare now than scramble when you are sick. Clean out clutter and stock up on the staples!
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Four-time PGA TOUR winner Tim Herron is teaming up with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP), Damon Adamany, MD, of The CORE Institute and the Facts on Hand campaign to educate adults about one of the more common hand conditions. The campaign is raising awareness of Dupuytren’s Contracture, a progressive, potentially disfiguring hand condition affecting a layer of tissue underneath the palms that can cause one or more fingers to move into a bent position so they cannot be straightened.
Dupuytren’s Contracture, sometimes referred to as “Viking Disease,” can make everyday tasks difficult, such as grabbing an object at home, or in Tim Herron’s case, a nine iron from his golf bag. Many people live with the disease without being diagnosed because they mistakenly assume they have arthritis or another hand condition. And because Dupuytren’s Contracture may progress slowly, people may not pay attention to it until they can no longer straighten their fingers, complicating everyday activities.
To view the multimedia release go to:
https://www.multivu.com/players/English/8153851-endo-facts-on-hand-dupuytrens-contracture/
A new survey from Alcon, the global leader in eye care and a division of Novartis, demonstrates that people experience significant emotional and lifestyle benefits after cataract surgery. Nearly three in four respondents who expressed an opinion agreed that after having the surgery, they were happier, more satisfied and had a greater appreciation for life. The survey also confirmed that life before surgery posed several daily challenges. A majority of survey respondents said cataracts made simple, day-to-day tasks harder, and made them feel annoyed, frustrated and old.
In recognition of Cataract Awareness Month this June, Alcon conducted the MyCataracts survey with 1,300 US adults, age 60 and over, who have undergone cataract surgery, to better understand the emotional journey of the condition and the lifestyle benefits of treatment. The survey expands Alcon’s ongoing MyCataracts awareness campaign by uncovering insights that will help people make informed treatment decisions together with their doctors.
To view the multimedia release go to:
https://www.multivu.com/players/English/8068751-alcon-pharmaceuticals-my-cataracts-eye-care/
